Daix
(France),
Long Island City (
New York, USA)
,
1
er
March 2022
– Inventiva (Euronext Paris and Nasdaq: IVA), a biopharmaceutical company specializing in the clinical development of orally administered small molecules for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with unmet medical need, announces today today that its management team will participate in two investor conferences during the month of March 2022.
The event details are as follows:
|
Conference n°1: Event type : date: Presentation of Inventiva: Size: Link (live & replay): |
” Cowen 42nd Annual Health Care Conference » |
|
Conference n°2: Event type : date: Time : Size: Location : | “Invest securities Biomed Event” |
The link to access the event will also be available on the Inventiva website in the “Investors – Investor Presentations” section.
About Inventiva
Inventiva is a biopharmaceutical company specializing in the clinical development of orally administered small molecules for the treatment of NASH and other diseases with significant unmet medical need.
Leveraging its expertise and significant experience in the development of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently developing lanifibranor as well as other early-stage programs.
Lanifibranor, Inventiva’s lead drug candidate, is currently in development for the treatment of patients with NASH, a common and progressive chronic liver disease for which there is currently no approved treatment. In 2020, Inventiva published positive results from its Phase IIb clinical study evaluating lanifibranor for the treatment of patients with NASH and obtained “Breakthrough Therapy” and “Fast Track” status from the
Food and Drug Administration
(FDA) for lanifibranor in the treatment of NASH. Lanifibranor is currently being evaluated in a pivotal Phase III clinical study.
Inventiva’s portfolio also includes odiparcil, a drug candidate for the treatment of patients suffering from a subtype of MPS, a group of rare genetic diseases. In 2019, Inventiva published positive results from its Phase IIa clinical study evaluating odiparcil for the treatment of adult patients with MPS VI and obtained “Fast Track” and “rare pediatric disease” status from the US FDA for odiparcil in MPS VI. As part of its decision to focus its clinical efforts on the development of lanifibranor, Inventiva has suspended clinical efforts relating to odiparcil and is examining all possible options to optimize its development.
The company also entered into a strategic partnership with AbbVie in the area of autoimmune diseases which led to the discovery of the drug candidate cedirogant (AABV-157), an orally administered RORg inverse agonist. Cedirogant has shown promising activity as an oral drug candidate for the treatment of psoriasis in a Phase Ib clinical study and a Phase IIb clinical study in patients with moderate to severe chronic plaque psoriasis is currently underway. This collaboration allows Inventiva to receive payments upon reaching preclinical, clinical, regulatory and commercial milestones, in addition to royalties on the sales of products developed under this partnership.
At the same time, Inventiva is in the process of selecting a drug candidate in oncology for its program in the Hippo signaling pathway.
The Company has a scientific team of approximately 70 people with strong expertise in biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. In addition, Inventiva has a chemical library of approximately 240,000 molecules, of which approximately 60% are the property of the Company, as well as its own laboratories and equipment.
Inventiva is listed on compartment C of the regulated market of Euronext Paris (Euronext Paris: IVA – ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (symbol: IVA).
www.inventivapharma.com
.
contacts
Attachment
Inventiva – PR – Events IR March – 29 02 2022